|
12.12.2024 14:37:53
|
Trevi Reports Positive Outcome From Sample Size Re-estimation For Phase 2b CORAL Study; Stock Up
(RTTNews) - Trevi Therapeutics, Inc. (TRVI) Thursday reported positive outcome from sample size re-estimation for the ongoing Phase 2b CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) who have chronic cough. The clinical-stage biopharmaceutical company's shares were surging more than 80 percent in pre-market.
Based on the Sample size re-estimation (SSRE), a method that allows to change the sample size of a clinical trial during its conduct, the current sample size of 160 is not required to change. The study has already reached 75 percent enrollment.
The company continues to expect topline data from the study in the first half of 2025.
Trevi stock had closed at $2.49, down 7.09 percent on Wednesday. It has traded in the range of $2.36 - $2.73 in the last 1 year.
Analysen zu Trevi Therapeutics Inc Registered Shs
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Trevi Therapeutics Inc Registered Shs | 3.55 | -5.84% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Trump-Effekt hält an: SMI im Plus -- DAX deutlich höher - neues Rekordhoch -- Asiens Börsen letztlich mehrheitlich in RotDer heimische sowie der deutsche Aktienmarkt zeigen sich am Mittwoch mit Gewinnen. Der DAX erreicht dabei sogar eine neue Bestmarke. Die Börsen in Fernost notierten zur Wochenmitte überwiegend im Minus.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |